Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Anebulo Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS, INC. (NASDAQ: ANEB), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING NOVEL SOLUTIONS FOR PEOPLE SUFFERING FROM ACUTE CANNABIS-INDUCED TOXIC EFFECTS (THE COMPANY OR ANEBULO), TODAY ANNOUNCED THAT A SPECIAL COMMITTEE OF INDEPENDENT DIRECTORS HAS RECOMMENDED, AND ITS BOARD OF DIRECTORS (THE BOARD) HAS APPROVED, AS PART OF A GOING PRIVATE TRANSACTION, A REVERSE STOCK SPLIT AT A RATIO OF NOT LESS THAN 1-FOR-2,500 AND NOT GREATER THAN.

ANEBULO PHARMACEUTICALS APPROVES PLAN TO TERMINATE REGISTRATION OF ITS COMMON STOCK

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS, INC. (NASDAQ: ANEB), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING NOVEL SOLUTIONS FOR PEOPLE SUFFERING FROM ACUTE CANNABIS-INDUCED TOXIC EFFECTS (THE COMPANY OR ANEBULO), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025, AND RECENT UPDATES. THIRD QUARTER FISCAL YEAR 2025 AND SUBSEQUENT HIGHLIGHTS: ANEBULO IS PRIORITIZING THE ADVANCEMENT OF AN INTRAVENOUS SELONABANT AS A POTENTIAL TREATMENT FOR PEDIATRI.

ANEBULO PHARMACEUTICALS REPORTS THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS AND RECENT UPDATES

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS, INC. (NASDAQ: ANEB), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING NOVEL SOLUTIONS FOR PEOPLE SUFFERING FROM ACUTE CANNABIS-INDUCED TOXIC EFFECTS (THE COMPANY OR ANEBULO), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED DECEMBER 31, 2024, AND RECENT UPDATES. SECOND QUARTER FISCAL YEAR 2025 AND SUBSEQUENT HIGHLIGHTS: IN DECEMBER 2024, ANEBULO MET WITH FDA TO DISCUSS THE DEVELOPMENT OF INTRAVENOUS SELONABANT AND THE IN.

ANEBULO PHARMACEUTICALS REPORTS SECOND QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS AND RECENT UPDATES

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS ANNOUNCES POSITIVE REGULATORY UPDATE FOR SELONABANT IN ACUTE CANNABIS-INDUCED TOXICITY IN CHILDREN AND CAPITAL RAISE.

ANEBULO PHARMACEUTICALS ANNOUNCES POSITIVE REGULATORY UPDATE FOR SELONABANT IN ACUTE CANNABIS-INDUCED TOXICITY IN CHILDREN AND CAPITAL RAISE

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS REPORTS FOURTH QUARTER AND FISCAL YEAR 2024 FINANCIAL RESULTS AND RECENT UPDATES.

ANEBULO PHARMACEUTICALS REPORTS FOURTH QUARTER AND FISCAL YEAR 2024 FINANCIAL RESULTS AND RECENT UPDATES

BOSTON--(BUSINESS WIRE)--GALEHEAD DEVELOPMENT, LLC (GALEHEAD) AND RIVIAN AUTOMOTIVE, LLC (RIVIAN) HAVE ENTERED INTO AN AGREEMENT TO COLLABORATE ON THE DEVELOPMENT OF RENEWABLE ENERGY RESOURCES TAILORED TO RIVIAN'S LOCATIONAL AND ENVIRONMENTAL PRIORITIES. GALEHEAD WILL DEVELOP SOLAR PROJECTS WITH SPECIFIC CONSIDERATION FOR RIVIAN'S 3C FRAMEWORK. THE 3C FRAMEWORK IS A PROGRESSIVE PROCUREMENT STANDARD THAT COMMITS RIVIAN TO SOURCING RENEWABLE ENERGY FROM PROJECTS THAT HAVE A MEASURABLE POSIT.

GALEHEAD DEVELOPMENT TO COLLABORATE WITH RIVIAN AUTOMOTIVE ON RENEWABLE ENERGY PROJECT DEVELOPMENT

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS, INC. (NASDAQ: ANEB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL SOLUTIONS FOR PEOPLE SUFFERING FROM ACUTE CANNABINOID TOXICITIES THAT INCLUDE ACUTE CANNABINOID INTOXICATION (ACI) AND UNINTENTIONAL CANNABIS POISONING (THE COMPANY OR ANEBULO), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2024, AND RECENT UPDATES. THIRD QUARTER FISCAL YEAR 2024 AND SUBSEQUENT HIGHLIGHTS: ANEBULO PRIORITIZES DEVE.

ANEBULO PHARMACEUTICALS REPORTS THIRD QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND RECENT UPDATES

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS REPORTS SECOND QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND RECENT UPDATES.

ANEBULO PHARMACEUTICALS REPORTS SECOND QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND RECENT UPDATES

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND RECENT UPDATES.

ANEBULO PHARMACEUTICALS REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND RECENT UPDATES

AUSTIN, TEXAS--(BUSINESS WIRE)--ANEBULO PHARMACEUTICALS, INC. (NASDAQ: ANEB), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL SOLUTIONS FOR PEOPLE SUFFERING FROM ACUTE CANNABINOID INTOXICATION (ACI) ("ANEBULO"), TODAY ANNOUNCED THE APPOINTMENT OF BIMAL SHAH TO ITS BOARD OF DIRECTORS. MR. SHAH WILL SERVE AS A MEMBER OF THE BOARD'S AUDIT AND COMPENSATION COMMITTEES. "I AM PLEASED TO WELCOME BIMAL TO THE ANEBULO BOARD," SAID DR. JOSEPH LAWLER, ANEBULO'S CHAIRMAN. "BIMAL'S DEPTH OF FINA.

Anebulo Pharmaceuticals, Inc.

ANEB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Anebulo Pharmaceuticals, Inc.

ANEB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ANEB